roypounder.apt

@APandT new papers in AP&T, summaries free-to-view. 2023 Impact Factor is 6.6, ranking AP&T 18/97 for journals in Gastroenterology & Hepatology.

[roypounder.apt @APandT]

This study highlights kidney disease as a predictor of PBUB together with the well-established higher risk for urgent band ligation.
Read the full paper 'open access' via https://t.co/01zoRdvtKJ
#PBUB #cirrhosis #livertwitter

[roypounder.apt @APandT]

This study reviews existing research on the use of GLP-1 receptor agonists in managing GI diseases and finds that early evidence suggests these agents hold promise across multiple conditions. Read the full review via https://t.co/Eu4BrooUDJ
#GItwitter #GLP1

[roypounder.apt @APandT]

"A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease".
Read the findings via open access at https://t.co/Rt8nSxLGVl
#GItwitter #IBD

[roypounder.apt @APandT]

Indocyanine green clearance by pulse dye densitometry correlates with portal hypertension, systemic inflammation and circulatory dysfunction in advanced chronic liver disease. Read the full paper, open access, via https://t.co/AtmpO2ZHwo
#livertwitter

[roypounder.apt @APandT]

"Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis" by Kowdley et al now available to read via https://t.co/X9yzCnE182
#PBC #livertwitter

[roypounder.apt @APandT]

Read via https://t.co/Ffm9bxSopi "Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease"
#Gitwitter #IBD #pregnancy #CLD #livertwitter

[roypounder.apt @APandT]

Read open access via https://t.co/rEJmvU8raP this secondary analysis of the MAESTRO-NASH trial which examined the effects of resmetirom in patients with weight loss and/or treated with therapies for T2D.
#livertwitter #resmetirom #MASH

[roypounder.apt @APandT]

Meta-analysis on irAEs, particularly dermatologic, endocrine and low-grade events, were associated with improved ICIs effectiveness in HCC.
Read the full paper via https://t.co/2cV3zj9yK8
#livertwitter #HCC #ICIs

[roypounder.apt @APandT]

"Clinical Trial: Simplified Bowel Preparation for Small Bowel Capsule Endoscopy in Crohn's Disease" available to read via https://t.co/WPAQfIVN97
#GItwitter #bowelprep #SBCE #IBD

[roypounder.apt @APandT]

Read via https://t.co/IoYHy2dna8
"Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow-Up Study" by Riggott et al
#IBD #depression #GITwitter

[roypounder.apt @APandT]

"Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study" available to read 'open access' via https://t.co/M7FnetOXdC
#GItwitter

[roypounder.apt @APandT]

"Alterations in Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension: Implications for Disease Progression" is now available to read 'open access' via https://t.co/TfzSkyeOoE
#livertwitter #portalhypertension #microbiota

[roypounder.apt @APandT]

@APandT 15th October 2025 issue is now online at https://t.co/dZoUdtRGMt
#GItwitter #livertwitter #IBD #coeliac #MELD #AKI #Hpylori #IUS #DGBI

[roypounder.apt @APandT]

Read open access via https://t.co/J37ZBiPwWt
"Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH"
#livertwitter #MASH #semaglutide #NITs

[roypounder.apt @APandT]

Can we manage IBD while reducing healthcare’s carbon footprint? This systematic review shows intestinal ultrasound is a low-carbon alternative to traditional options. A step toward sustainable IBD care.
Read the full review via https://t.co/ABEQ8XaNOC
#GItwitter #IBD

[roypounder.apt @APandT]

Read 'open access' via https://t.co/QqGw8vbTM2 the multi-centre study of obeticholic acid in primary biliary cholangitis by Abbas et al.
#livertwitter #PBC #obeticholicacid

[roypounder.apt @APandT]

34 studies including 1586 patients with severe alcohol-associated hepatitis found pooled mortality rates of 26.8% at 28 days, 35.1% at 60 days, and 43.7% at 90 days. Read the full meta-analysis 'open access' via https://t.co/l7Tc8IcvQm
#livertwitter #sAH

[roypounder.apt @APandT]

Read 'open access' the "Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5-Aminosalicylate for Ulcerative Colitis—The EASI Trial" via https://t.co/PR9O0i4eKV
#GItwitter #ulcerativecolitis #IBD #EASItrial

[roypounder.apt @APandT]

Read 'open access' via https://t.co/WE7rAEeJmG "Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver Disease"
#livertwitter #HepB #MASLD #hcc

[roypounder.apt @APandT]

'Free to read' via https://t.co/FauSU9jShH
"Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease"
by Mahadevan et al
#IBD #GItwitter #pregnancy